Last reviewed 2026-06-03 · How we verify

Corrigen (OLEANDRIN)

Phase 1 active Small molecule ✓ Verified Jun 2026

Corrigen (generic name: OLEANDRIN) is a oleandrin drug. It is currently in Phase 1 development.

Corrigen works by interacting with cellular targets to produce its therapeutic effects.

Corrigen is a small molecule modality. It is also known by the synonyms ANVIRZEL, NSC-692219, OLEANDRIN, and OLEANDRIN.

Likelihood of approval

6.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	OLEANDRIN
Drug class	oleandrin
Target	Neurogenic locus notch homolog protein 1
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 1

Mechanism of action

Imagine Corrigen as a key that unlocks a specific process in the body, allowing it to function properly. This process is crucial for maintaining health, but when it's disrupted, it can lead to disease. By restoring balance to this process, Corrigen may help alleviate symptoms and improve overall well-being.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Corrigen CI brief — competitive landscape report
Corrigen updates RSS · CI watch RSS

Frequently asked questions about Corrigen

What is Corrigen?

Corrigen (OLEANDRIN) is a oleandrin drug.

How does Corrigen work?

Corrigen works by interacting with cellular targets to produce its therapeutic effects.

What is the generic name of Corrigen?

OLEANDRIN is the generic (nonproprietary) name of Corrigen.

What drug class is Corrigen in?

Corrigen belongs to the oleandrin class. See all oleandrin drugs at /class/oleandrin.

What development phase is Corrigen in?

Corrigen is in Phase 1.

What does Corrigen target?

Corrigen targets Neurogenic locus notch homolog protein 1 and is a oleandrin.

Drug class: All oleandrin drugs
Target: All drugs targeting Neurogenic locus notch homolog protein 1
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing